Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Livongo Health, Inc. (LVGO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/30/2020 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LIVONGO HEALTH, INC. 1. Name . The name of the corporation is Livongo Health, Inc. . 2. Address; Registered Office and Agent . The name and address of the Corporation’ s registered agent is Corporation Service Company, 251 Little Falls Drive in the City of Wilmington, County of New Castle, Delaware, 19808. 3. Purpose . The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware . 4. Number of Shares . The total number of shares of stock that the Corporation shall have authority to issue is 1,000, all of which shall be shares of Common Stock with the par value of $0.01 per share. 5. Election of Directors . Unless and except to ...",
"BYLAWS OF LIVONGO HEALTH, INC. ARTICLE I Meetings of Shareholders: Shareholders’ Consent in Lieu of Meeting Section 1.01. Annual Meeting . The annual meeting of the shareholders for the election of directors, and for the transaction of such other business as may properly come before the meeting, shall be held at such place, date and hour as shall be fixed by the Board of Directors and designated in the notice or waiver of notice thereof; except that no annual meeting need be held if all actions, including the election of directors, required by the General Corporation Law of the State of Delaware to be taken at a shareholders’ annual meeting are taken by written consent in lieu of meeting pursuant to Section 1.03 of this Article. Section 1.02. Special Meetings . A special meeting of the sha...",
"LIVONGO HEALTH, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 4, 2020 0.875% Convertible Senior Notes due 2025",
"FIRST SUPPLEMENTAL INDENTURE",
"This WAIVER, CONSENT AND FOURTH Amendment to Loan and Security Agreement is entered into this 30th day of October, 2020, by and between SILICON VALLEY BANK, a California corporation , and LIVONGO HEALTH, INC., a Delaware corporation (“Borrower"
10/30/2020 8-K Submission of Matters to a Vote of Security Holders, Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report : October 29, 2020 Livongo Health, Inc. Delaware 001-38983 26-3542036 150 West Evelyn Avenue, Suite 150 Mountain View, California 94041 435-5643 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-..."
10/29/2020 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report : October 29, 2020 Livongo Health, Inc. Delaware 001-38983 26-3542036 150 West Evelyn Avenue, Suite 150 Mountain View, California 94041 435-5643 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-..."
10/28/2020 8-K Quarterly results
Docs: "Livongo Reports Third Quarter 2020 Financial Results"
10/16/2020 8-K Quarterly results
10/09/2020 8-K Quarterly results
09/21/2020 8-K Quarterly results
09/16/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Teladoc Health and Livongo File Definitive Proxy Statement"
08/05/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
07/07/2020 8-K Quarterly results
06/04/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 1, 2020 Livongo Health, Inc. Delaware 001-38983 26-3542036 150 West Evelyn Avenue, Suite 150 Mountain View, California 94041 Registrant's telephone number, including area code: 435-5643 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ...",
"Indenture, by and between Livongo Health, Inc. and U.S. Bank National Association, as Trustee",
"Purchase Agreement, by and among Livongo Health, Inc. and Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC",
"Form of Confirmation for Capped Call Transactions",
"Second Amendment to Loan and Security Agreement, among the Company, as borrower and Silicon Valley Bank, as lender",
"Third Amendment to Loan and Security Agreement, among the Company, as borrower and Silicon Valley Bank, as lender",
"Livongo Announces Proposed Offering of $400.0 Million of Convertible Senior Notes Due 2025",
"Livongo Announces Pricing of Upsized $475.0 Million Convertible Senior Notes Offering"
05/22/2020 8-K Submission of Matters to a Vote of Security Holders
05/06/2020 8-K Quarterly results
04/07/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Livongo Announces Preliminary First Quarter 2020 Revenue; Exceeds Previously Announced Guidance First Quarter 2020 Earnings Conference Call Scheduled for May 6, 2020"
03/27/2020 8-K Quarterly results
03/02/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
Docs: "Livongo Reports Third Quarter Financial Results • Third quarter Total Revenue of $46.7 million, up 148% year-over-year • 207,815 enrolled Livongo for Diabetes Members, up 118% year-over-year • 2019 revenue guidance range raised to between $168.5 million and $169.0 million"
10/07/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Livongo Awarded Diabetes Contract for Eligible Population for Approximately 5.3 Million Beneficiaries Through the Federal Employees Health Benefits Program"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy